Eisai Press Release


Eisai Selected as Competitive ICT Strategy Company for 2019
Apr 24, 2019 08:36 JST
Eisai Co., Ltd. has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Competitive IT Strategy Company 2019 as a company that is engaged in the strategic utilization of IT.
More info..

Eisai: Japan MHLW Grants Sakigake Designation to Novel Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor E7090
Apr 08, 2019 13:06 JST
Eisai Co., Ltd. has announced that its in-house discovered fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor E7090 has been granted the SAKIGAKE designation by Japan's Ministry of Health, Labour and Welfare for the treatment of unresectable biliary tract cancer with FGFR2 gene fusion.
More info..

Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
Apr 08, 2019 10:43 JST
Eisai Co., Ltd. will launch its new carbonated beverage Chocola BB Sparkling Kiwi & Lemon Flavor, classified as a Food with Nutrient Function Claims, in Japan on Tuesday, April 9.
More info..

Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug
Apr 05, 2019 09:45 JST
Eisai Co., Ltd. will launch the mouth freshener Travelmin Support as the first quasi-drug of the Travelmin series which can be purchased even at convenience stores and others in Japan on Monday, April 8.
More info..

Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease
Mar 29, 2019 10:46 JST
Eisai Co., Ltd. announced today that in the 8th meeting of the Data Safety Monitoring Board (DSMB) for the global Phase III clinical studies (MISSION AD) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in early Alzheimer's disease (AD).
More info..

Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease
Mar 22, 2019 10:37 JST
Eisai Co., Ltd. announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen Inc.
More info..

Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases
Mar 22, 2019 10:23 JST
Eisai Co., Ltd. announced that a total of seven presentations highlighting the latest data on its Alzheimer's disease/dementia pipeline, including anti-amyloid beta (Abeta) protofibril antibody BAN2401 and oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat will be given at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD).
More info..

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease
Mar 21, 2019 23:25 JST
Biogen and Eisai, Co., Ltd. announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia.
More info..

Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
Mar 12, 2019 07:43 JST
Eisai Co., Ltd. and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma, L.P. have announced that the U.S. FDA has accepted for review the NDA for lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder.
More info..

Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan
Mar 07, 2019 11:30 JST
Eisai Co., Ltd. announced today that a marketing authorization application has been submitted in Japan for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for use in the treatment of insomnia disorder.
More info..

Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan
Feb 27, 2019 10:52 JST
Eisai Co., Ltd. has entered an agreement to support the international non-governmental organization Association for Aid and Relief, Japan's program to raise awareness of mycetoma in Sudan.
More info..

AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
Feb 21, 2019 13:50 JST
AbbVie, a research-based global biopharmaceutical company and Eisai Co., Ltd. announced that they have received approval for an additional indication of HUMIRA (generic name: adalimumab [recombinant]), a fully human anti-TNF-alpha monoclonal antibody, for the treatment of hidradenitis suppurativa (HS).
More info..

Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy
Feb 13, 2019 08:29 JST
Eisai Co., Ltd. announced today that it has submitted an application to the European Medicines Agency (EMA) for its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) seeking approval for use in pediatric patients with epilepsy.
More info..

Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study
Feb 04, 2019 11:57 JST
Eisai Co., Ltd. and Purdue Pharma L.P. announced a six-month results from SUNRISE 2, a long-term Phase 3 clinical study evaluating the efficacy and safety of lemborexant, an investigational agent being developed for the treatment of insomnia, a sleep-wake disorder.
More info..

Eisai's Supplementary New Drug Application Submitted In Japan for Fycompa
Jan 30, 2019 15:22 JST
Eisai Co., Ltd. has filed a supplementary new drug application in Japan for its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) seeking approval for use as monotherapy for partial-onset seizures, treatment for partial-onset seizures in pediatric patients aged 4 years and older, as well as a new fine granule formulation.
More info..

Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time
Jan 22, 2019 16:54 JST
Eisai Co., Ltd. has been listed in the 2019 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc.
More info..

Eisai's Notification Regarding Results of Voluntary Retirement Program
Jan 18, 2019 13:33 JST
Eisai Co., Ltd. announced today that the application period for the first round of the voluntary retirement program it announced on October 25, 2018, has ended and hereby discloses the results.
More info..

Eisai to Present Results of Post-Hoc Analyses of Lenvima (Lenvatinib) Phase III Reflect Study in Hepatocellular Carcinoma at 2019 Gastrointestinal Cancers Symposium
Jan 15, 2019 13:31 JST
Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting the latest data from post-hoc analyses of a Phase III clinical study (REFLECT/Study 304) on its in-house discovered multiple receptor tyrosine kinase inhibitor lenvatinib mesylate as first-line treatment for unresectable hepatocellular carcinoma (HCC) will be presented during the 2019 Gastrointestinal Cancers Symposium (ASCO-GI) in San Francisco.
More info..

Eisai's New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
Jan 15, 2019 13:23 JST
Eisai Co., Ltd. and Purdue Pharma L.P. today announced that a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for the treatment of insomnia, a sleep-wake disorder.
More info..

Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards
Jan 04, 2019 11:18 JST
Eisai Co., Ltd. has announced that it received a "Nikkei Business Daily Awards for Superiority" for its Etak Antimicrobial Spray Alpha, which contains long-acting antimicrobial agent Etak, at the 2018 Nikkei Superior Products and Services Awards sponsored by Nikkei Inc.
More info..

Eisai's New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration
Jan 04, 2019 08:39 JST
Eisai Co., Ltd. announced that its in-house discovered and developed AED perampanel, for which a NDA was submitted for review as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older in China in October 2018, has been designated for Priority Review by the NMPA due to perampanel's significant clinical benefit compared to existing treatments.
More info..

Eisai: Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform
Dec 18, 2018 10:38 JST
Bristol-Myers Squibb Company, Eisai Co., Ltd. and its U.S.-based precision medicine research & development subsidiary H3 Biomedicine, Inc. has announced a multi-year research collaboration focused on evaluating whether novel therapeutics leveraging H3's RNA splicing platform can provide a more powerful response against cancer.
More info..

Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Brazil with Eurofarma
Dec 17, 2018 08:21 JST
Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for sales in Brazil.
More info..

GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics
Dec 12, 2018 09:06 JST
The Global Antibiotic Research and Development Partnership (GARDP), Eisai Co., Ltd. and Takeda Pharmaceutical Company Limited have signed an agreement for GARDP to access and screen components of Eisai and Takeda's chemical libraries.
More info..

Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research
Dec 06, 2018 09:24 JST
Eisai Co., Ltd. and University College London (UCL) announced today that they have commenced preparations for Phase I clinical studies on E2814, the first clinical candidate from their drug discovery collaboration, in Alzheimer's disease patients within fiscal 2018.
More info..

Eisai: MOVICOL Launched in Japan
Nov 29, 2018 13:48 JST
MOVICOL is the first polyethylene glycol preparation indicated for treatment of chronic constipation in Japan, available for adults and children 2 years of age and older.
More info..

Eisai: Primary Endpoint Met in Phase III Clinical Study of Fycompa
Nov 28, 2018 10:55 JST
Eisai Co., Ltd. announced today that based on topline results, the primary efficacy endpoint was met in a Phase III clinical study (Study 342) conducted for submission in Japan, which evaluated its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) as monotherapy for partial-onset seizures.
More info..

Eisai to Present New Research on Eribulin (Halaven) at 41st Annual San Antonio Breast Cancer Symposium
Nov 27, 2018 17:02 JST
Eisai Co., Ltd. announced today that the latest information on its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented during the 41st San Antonio Breast Cancer Symposium (SABCS).
More info..

Eisai to Present Latest Data on Perampanel at 72nd American Epilepsy Society Annual Meeting
Nov 23, 2018 07:14 JST
Eisai Co., Ltd. announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 72nd American Epilepsy Society Annual Meeting (AES 2018) to be held from November 30 to December 4, 2018 in New Orleans in the United States.
More info..

Latest Release


More Latest Release >>